1. Scrip
  2. >>New Products

Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out

 
• By Jessica Merrill

The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.

Shelves
Biogen is shelving some pipeline assets to prioritize investment. • Source: Shutterstock

Biogen, Inc. underscored its commitment to Alzheimer’s disease while announcing the discontinuation of three clinical-stage development programs as new CEO Christopher Viehbacher continues to piece together a business strategy that will return the company to steady growth beginning in 2025. Executives updated investors on Biogen’s ongoing business review during its first quarter sales and earnings call on 25 April.

“What we’re really trying to do is redesign the company,” Viehbacher told the call.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.